Tecovirimat - SIGA Technologies

Drug Profile

Tecovirimat - SIGA Technologies

Alternative Names: Arestvyr; SIGA-246; ST-246®; TPOXX

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ViroPharma
  • Developer Biomedical Advanced Research and Development Authority; SIGA Technologies
  • Class Antivirals; Benzamides; Indoles; Small molecules
  • Mechanism of Action Viral envelope protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Smallpox; Orthopoxvirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Smallpox
  • Phase III Orthopoxvirus infections

Most Recent Events

  • 11 Dec 2017 SIGA Technologies expects to receive notification from the US FDA that the NDA filing was accepted for review, confirmation of priority review status and notification of its final action date for Small pox in February 2018
  • 11 Dec 2017 SIGA Technologies requests a priority review to the US FDA for tecovirimat's NDA for Smallpox (Adjunctive treatment) (PO)
  • 08 Dec 2017 Preregistration for Smallpox (Adjunctive treatment) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top